Predictive value of peripheral blood inflammatory markers on immunotherapy efficacy in advanced non-small cell lung cancer
Objective To investigate the predictive value of peripheral blood inflammatory markers on immunotherapy efficacy and prognosis in advanced non-small cell lung cancer(NSCLC).Methods In this retrospective study,totally 107 patients with advanced NSCLC received immunotherapy in our hospital from January 2020 to June 2022 were enrolled.The neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)were collected before immunotherapy,and the optimal cut-off values of NLR and PLR were determined according to the receiver operating characteristic(ROC)curve for verifying the short-term and long-term efficacy of immunotherapy in advanced NSCLC.Results ROC analysis showed that the optimal cut-off value of NLR and PLR was 3.825,and 179,respectively.The short-term efficacy analysis showed that the levels of disease control rate(DCR)in the high NLR group were significantly lower than those of the low NLR group(54.3％vs 83.3％,P=0.001).The levels of DCR in the high PLR group were significantly lower than those of the low PLR group(59.0％vs 82.4％,P=0.008).No differences were observed in objective response rate(ORR)between the two groups.Kaplan-Meier survival curve showed that the median progression-free survival(PFS)(11.0 months vs 6.0 monthsP=0.014)and overall survival(OS)(11.0 months vs 8.0 months,P=0.032)in the low NLR group were significantly higher than those of the high NLR group.Similarly,the median PFS(11.0 months vs 6.0 months,P=0.034)and OS(12.0 months vs 11.0 months,P=0.045)in the low PLR group were significantly higher than those of the high PLR group.Conclusion Low baseline levels of NLR and PLR are positively correlated with immunotherapy efficacy and prognosis in advanced NSCLC,which are important indicators for predicting immunotherapy efficacy in patients with advanced NSCLC.
万方数据
维普
